CCR8 is a GPCR mainly expressed in tumor-infiltrating T-regulatory cells (Treg) and high CCR8 expression is associated with poor prognosis in cancer. CCR8 and its ligand CCL1 may be involved in Treg recruitment, conversion and/or immunosuppressive function. Recently, pharmacological inhibition of CCR8 in mouse models has been reported to result in tumor regression and small molecule inhibitors of CCR8 have entered the clinic. Aiming to find a new class of CCR8 antagonists, a high throughput screen (HTS) of the Idorsia compound library was performed. HTS hits with a promising profile were identified and subsequent characterization revealed hERG as a key parameter that required further optimization. We reasoned that a strategy focused on discrete structural modifications would offer significant potential to reduce hERG inhibition. The lead optimization campaign we report led to the identification of compound 52 (IDOR-1136-5177), a highly potent CCR8 antagonist representing a new chemical class of CCR8 inhibitors with excellent in vitro and in vivo properties.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/cmdc.202400968 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Design and application of CCR8 antagonists.
Future Med Chem
March 2025
KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Molecular, Structural and Translational Virology Research Group, Leuven, Belgium.
Discovery of CCR8 Antagonist IDOR-1136-5177 for the Treatment of Cancer.
ChemMedChem
February 2025
Drug Discovery, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, CH-4123, Allschwil, Switzerland.
CCR8 is a GPCR mainly expressed in tumor-infiltrating T-regulatory cells (Treg) and high CCR8 expression is associated with poor prognosis in cancer. CCR8 and its ligand CCL1 may be involved in Treg recruitment, conversion and/or immunosuppressive function. Recently, pharmacological inhibition of CCR8 in mouse models has been reported to result in tumor regression and small molecule inhibitors of CCR8 have entered the clinic.
View Article and Find Full Text PDFPreclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs.
Cancer Immunol Immunother
August 2024
Mabwell (Shanghai) Bioscience Co., Ltd, Shanghai, 201210, China.
Article Synopsis
- Anti-CTLA-4 antibodies encountered issues like frequent side effects and limited effectiveness, prompting research into advanced CTLA-4 therapies that better deplete regulatory T cells while activating CD8 T cells.
- CCR8, primarily found on tumor-infiltrating Tregs, emerged as a significant target due to its ability to promote anti-tumor responses through Treg depletion.
- The newly developed bispecific antibody 2MW4691 selectively targets CCR8 and CTLA-4, enhancing T cell activation and selectively depleting Tregs, demonstrating promising in vitro and in vivo efficacy with minimal side effects, warranting further clinical trials.
CCL16 is a pro-tumor chemokine that recruits monocytes and macrophages to promote hepatocellular carcinoma progression.
Am J Cancer Res
July 2024
Liver Research Center, Chang Gung Memorial Hospital Linkou, Taoyuan 333, Taiwan.
Article Synopsis
- Scientists are studying how a protein called CCL16 affects liver cancer (HCC) and found that high levels of it can lead to worse outcomes for patients.
- In lab tests, they saw that CCL16 makes cancer cells grow faster and helps recruit certain immune cells to the tumors.
- Their research suggests that blocking CCL16 could be a new way to treat liver cancer by stopping it from helping tumors grow.
Targeting the glucocorticoid receptor-CCR8 axis mediated bone marrow T cell sequestration enhances infiltration of anti-tumor T cells in intracranial cancers.
Cell Mol Immunol
October 2024
The Third Affiliated Hospital of Soochow University, Institutes for Translational Medicine, State Key Laboratory of Radiation Medicine and Protection, Soochow University Suzhou Medical College, Suzhou, Jiangsu, China.
Brain tumors such as glioblastomas are resistant to immune checkpoint blockade therapy, largely due to limited T cell infiltration in the tumors. Here, we show that mice bearing intracranial tumors exhibit systemic immunosuppression and T cell sequestration in bone marrow, leading to reduced T cell infiltration in brain tumors. Elevated plasma corticosterone drives the T cell sequestration via glucocorticoid receptors in tumor-bearing mice.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!